Enanta Pharmaceuticals Inc. (ENTA) is a leading research and development-based biotechnology company that specializes in discovering and developing small molecule drugs for the treatment of viral and liver diseases. Founded in 1995 and headquartered in Watertown, Massachusetts, ENTA primarily focuses on viral infections, including Hepatitis B, respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV).
The company is recognized for its significant role in the creation and development of direct-acting antivirals for Hepatitis C, thus changing the treatment paradigm for this chronic, severe liver disease. In addition to Hepatitis C, its portfolio also includes inhibitors of clinical and preclinical stages that target liver and respiratory diseases.
Enanta Pharmaceuticals operates primarily through two segments: Research and Development and Royalty Revenue. The Research and Development segment is involved in the creation and advancement of its disease targets pipeline, while the Royalty Revenue segment generates income from the royalties of antiviral products' sales developed by its partner, AbbVie.
Enanta's partnerships and collaborations have played a significant role in its journey towards reshaping the health industry's landscape. It has a long-standing alliance with AbbVie, resulting in two significant, marketed direct-acting antivirals, MAVYRET™ (glecaprevir/pibrentasvir) and VIEKIRA PAK® (paritaprevir/ritonavir/ombitasvir/dasabuvir).
Enanta Pharmaceuticals' innovative approach extends to an extensive pipeline of other potential advancements, including a core inhibitor for Hepatitis B, non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other targeted treatments. The company’s strong commitment to the research and development of novel therapies and their efficiency and safety underscores its long-term vision of making a significant contribution to global healthcare.
Enanta Pharmaceuticals adheres to the highest ethical standards in conducting its business and adheres to a rigorous code of conduct while dealing with patients, healthcare providers, and regulatory authorities worldwide. This commitment to integrity and transparency has earned the company trust and respect in the industry. In conclusion, Enanta Pharmaceuticals embodies the spirit of innovation and expert scientific exploration, bringing cutting-edge therapies to the market and dramatically impacting patients' lives.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Enanta Pharmaceuticals has dosed the first patient in its global Phase 2b/3 RESOLVE trial for zelicapavir, an antiviral treatment for RSV in high-risk adults. The study aims to evaluate symptom resolution and hospitalization rates, building on encouraging results from an earlier Phase 2 study. Enanta anticipates releasing topline Phase 2b results for RESOLVE in 2027, alongside data from its pediatric LOTUS trial, as it works towards potential regulatory approval for zelicapavir.
Enanta Pharmaceuticals has initiated a late-stage trial for its oral RSV treatment, zelicapavir, dosing the first patient in the RESOLVE study. The Phase 2b portion will enroll at least 200 high-risk adults, with results anticipated in 2027, focusing on symptom recovery and hospitalization. This trial aims to confirm the treatment's effect size and build upon earlier findings that suggested a benefit in symptom resolution for high-risk subgroups.
This article analyzes Enanta Pharmaceuticals Inc. (ENTA) using AI models to provide trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, with a significant risk-reward setup. The analysis includes specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies.